2-(2,6-Dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione

Catalog No.: 
ACPXMQ758
CAS No.: 
835616-60-9
Molecular Formula: 
C13H9FN2O4
Molecular Weight: 
276.22
2-(2,6-Dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g98%$88.00In stockIn stock
100g98%$296.00In stockIn stock
500g98%$1478.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(2,6-Dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione
IUPAC Name2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione
MDL No.MFCD11840666
Molecular FormulaC13H9FN2O4
Molecular Weight276.22
SMILESO=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3F)=O
InChI KeyCRAUTELYXAAAPW-UHFFFAOYSA-N
Synonym835616-60-9 | 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione | Thalidomide 4-fluoride | E3 ligase Ligand 4 | 2-(2,6-Dioxo-piperidin-3-yl)-4-fluoroisoindoline-1,3-dione | Thalidomide fluoride | 4-Fluoro-thalidomide | TC E3 5032 | 1H-Isoindole-1,3(2H)-dione, 2-(
CAS No.835616-60-9
PubChem CID11859051

Synthetic Route by SureRoute

1. ACPXMQ758 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACQVBJ321 route compound structure diagram
    ACQVBJ32124666-56-6In Stock
  2. Plus
  3. ACHXVT489 route compound structure diagram
    ACHXVT489652-39-1In Stock
  4. Then
  5. ACPXMQ758 route product structure diagram
    ACPXMQ758835616-60-9In Stock
Inquiry

2. ACPXMQ758 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPXMQ758 route product structure diagram
    ACPXMQ758835616-60-9In Stock
Inquiry

3. ACPXMQ758 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPXMQ758 route product structure diagram
    ACPXMQ758835616-60-9In Stock
Inquiry

Comments (0)